714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Mycobacterium Obuense Colorectal Cancer	AIO-Studien-gGmbH	P2	CC (45)
Petrozumab Colorectal Cancer	Oslo University Hospital	P2	CC (45)
rbs2418 Colorectal Cancer	Riboscience, LLC.	P2	CC (45)
Ribociclib Colorectal Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P1/2	CC (45)
Rmc-9805 Colorectal Cancer	Revolution Medicines, Inc.	P1/2	CC (45)
sc0191 Colorectal Cancer	Tianshu Liu	P2	CC (45)
Sotevtamab Colorectal Cancer	Alethia Biotherapeutics	P2	CC (45)
Ssgj-707 Colorectal Cancer	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	P2	CC (45)
Taiwanofungus Camphoratus Fruiting Body Colorectal Cancer	Taiwan Leader Biotech Corp.	P1/2	CC (45)
T-Dxd Colorectal Cancer	Iambic Therapeutics, Inc	P1/2	CC (45)
Tinodasertib Colorectal Cancer	AUM Biosciences Pte Ltd	P2	CC (45)
Tub-030 Colorectal Cancer	Tubulis GmbH	P1/2	CC (45)
Volitinib Colorectal Cancer	Fudan University	P1/2	CC (45)
Young Til Colorectal Cancer	National Cancer Institute (NCI)	P2	CC (45)
cft1946 Colorectal Cancer	C4 Therapeutics, Inc.	P1	CC (44)
dsp107 Colorectal Cancer	Kahr Bio Australia Pty Ltd	P2	CC (44)
Eras-007 Colorectal Cancer	Erasca, Inc.	P1/2	CC (44)
Futibatinib Colorectal Cancer	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	P2	CC (44)
[177lu]lu-dpi-4452 Colorectal Cancer	ITM Oncologics GmbH	P1/2	CC (43)
[68ga]ga-dpi-4452 Colorectal Cancer	ITM Oncologics GmbH	P1/2	CC (43)
[99mTc]Tc-HYNIC-FAPI Colorectal Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P1	CC (43)
Agen1423 Colorectal Cancer	Weill Medical College of Cornell University	P2	CC (43)
Aguix Colorectal Cancer	Brigham and Women's Hospital	P2	CC (43)
Aipalolitovorelizumab Colorectal Cancer	Yanqiao Zhang	P2	CC (43)
All Trans Retinoic Acid Colorectal Cancer	University of Texas Southwestern Medical Center	P2	CC (43)
Amb-05X Colorectal Cancer	M.D. Anderson Cancer Center	P2	CC (43)
Ametumumab Colorectal Cancer	Shanghai Celfuture Biotech Co., Ltd.	P2	CC (43)
Amt-676 Colorectal Cancer	Multitude Therapeutics Inc.	P2	CC (43)
Artesunate Colorectal Cancer	Metanoic Health Ltd.	P2	CC (43)
aur109 Colorectal Cancer	Aurigene Discovery Technologies Limited	P2	CC (43)
Bbo-10203 Colorectal Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P1	CC (43)
Bemalenograstim Alfa Colorectal Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CC (43)
Berzosertib Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
Bet Bromodomain Inhibitor Zen-3694 Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
bi 907828 Colorectal Cancer	Institut Bergonié	P2	CC (43)
Bms-986523 Colorectal Cancer	Bristol-Myers Squibb	P1/2	CC (43)
Bpi-572270 Colorectal Cancer	Betta Pharmaceuticals Co., Ltd.	P1/2	CC (43)
Ceralasertib Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
Ciprofloxacin Colorectal Cancer	Virginia Commonwealth University	P2	CC (43)
Claturafenib Colorectal Cancer	Pfizer	P1	CC (43)
Cyad-101 Colorectal Cancer	Celyad Oncology SA	P1	CC (43)
Darleukin Colorectal Cancer	Philogen S.p.A.	P1	CC (43)
dky709 Colorectal Cancer	Novartis Pharmaceuticals	P1	CC (43)
Eliglustat Colorectal Cancer	Chinese PLA General Hospital	P2	CC (43)
Elimusertib Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
Emavusertib Colorectal Cancer	National Cancer Institute (NCI)	P1	CC (43)
EMPM Colorectal Cancer	The Netherlands Cancer Institute	P1	CC (43)
Entrectinib Colorectal Cancer	Hoffmann-La Roche	P2	CC (43)
eo2040 Colorectal Cancer	Enterome	P2	CC (43)
Erfonrilimab Colorectal Cancer	Peking University Cancer Hospital & Institute	P2	CC (43)

Showing 301 to 350 of 714 assets

PreviousPage 7 of 15Next